What is William Blair’s Estimate for ZVRA FY2026 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for Zevra Therapeutics in a report issued on Wednesday, November 13th. William Blair analyst S. Corwin forecasts that the company will post earnings of $0.54 per share for the year. William Blair currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 177.96%. During the same quarter last year, the business earned ($0.40) EPS.

Other research analysts have also recently issued reports about the company. Maxim Group boosted their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Monday, September 30th. JMP Securities started coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective for the company. Guggenheim began coverage on shares of Zevra Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $20.00 target price on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $8.62 on Friday. Zevra Therapeutics has a twelve month low of $4.18 and a twelve month high of $9.21. The company has a market cap of $453.57 million, a P/E ratio of -4.38 and a beta of 1.93. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80. The company’s 50-day moving average price is $8.03 and its 200-day moving average price is $6.50.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZVRA. International Assets Investment Management LLC grew its stake in Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after buying an additional 5,940 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new position in shares of Zevra Therapeutics in the 1st quarter valued at approximately $64,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after purchasing an additional 2,452 shares during the period. Hunter Associates Investment Management LLC purchased a new position in Zevra Therapeutics in the 3rd quarter valued at $92,000. Finally, XTX Topco Ltd purchased a new position in Zevra Therapeutics during the 3rd quarter worth $94,000. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.